All In Biotech

BLA 125268 · Amgen

Nplate

Romiplostim · Subcutaneous · Thrombopoietin Receptor Agonist

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Aug 22, 2008

Approved uses

4

Original approval plus efficacy supplements

Registered trials

105

26 Phase 3, 19 recruiting

FAERS reports

15,183

11,695 serious, 2,656 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 23, 2026.

Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) 1.1 Patients with Immune Thrombocytopenia (ITP) Nplate is indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. 1.2 Patients with Hematopoietic Syndrome of Acute Radiation Syndrome Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.3) ] . Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to...

Mechanism: Nplate increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to endogenous TPO.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 28, 2021 Supplement 167 · Efficacy · priority review OrphanLabelLetterReview
  • Oct 17, 2019 Supplement 164 · Efficacy OrphanLabelLetter
  • Dec 14, 2018 Supplement 163 · Efficacy · priority review OrphanLabelLetter
  • Aug 22, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewLabelReview
1 products under this application
  • NPLATE · ROMIPLOSTIM 250MCG/0.5ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Romiplostim" as an intervention, any sponsor and status, largest first.

All 105 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • platelet count decreased1,778
  • drug ineffective1,768
  • off label use1,282
  • thrombocytopenia1,048
  • death1,016
  • platelet count abnormal962
  • therapeutic response decreased942
  • headache616
  • fatigue478
  • platelet count increased404
  • hospitalisation393
  • haemorrhage391

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200847
2009410
20101,850
20112,054
2012891
2013527
2014630
2015799
2016616
2017982
20181,124
2019612
2020522
2021536
2022605
2023826
2024790
2025687
2026675

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: NPlate (Romiplostim)

2024 spending

$17.6M

Beneficiaries

285

1,734 claims

Per beneficiary

$61,839

$2,809.92 per unit

View as table
YearSpending
2020$10,765,856
2021$11,537,407
2022$13,219,386
2023$13,864,764
2024$17,623,974

Part B: NPlate (Romiplostim) · HCPCS J2796

2024 spending

$362M

Beneficiaries

6,523

92,588 claims

Per beneficiary

$55,572

2024 ASP limit $98.57 per unit

View as table
YearSpending
2020$232,041,197
2021$248,357,392
2022$283,987,979
2023$323,220,820
2024$362,499,336

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 121 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.